![]() ![]() As we look to the future, we remain focused on advancing technologies that could. How Have Estimates Been Moving Since Then?Īnalysts were quiet during the last one month period as none of them issued any earnings estimate revisions. Our pipeline of cancer therapies in the areas of cell therapy, immuno-oncology, and targeted therapies includes investigational therapies and next-generation technologies that have the power to transform the way cancer is treated. The company does not expect to generate any product revenues from axicabtagene ciloleucel in 2017. Kite Pharma, Inc., is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on engineered autologous cell therapy (eACT) designed to restore the immune systems ability to recognize and eradicate tumors. Operating expenses are expected to be between $490 million and $515 million in 2017. Net cash burn in 2017 is expected to be between $325 million and $340 million. The increase was due to $409.7 million received from a follow-on offering of common stock and $50 million in upfront payment from Daiichi Sankyo. Kite Pharma ended the year with $804.0 million in cash and marketable securities compared with $414 million at the end of the fourth quarter last year. While Kite Pharma’s research and development expenses shot up 91.5% from the year-ago period to $65.9 million in the reported quarter, general and administrative expenses were $35.8 million, up 114.5% from the year-ago period. The gross proceeds to Kite from the offering, before deducting the underwriting discounts and commissions. (Nasdaq:KITE) today announced the pricing of an underwritten public offering of 3,625,000 shares of its common stock at a price to the public of 69.00 per share. In the quarter, the company recognized $5.5 million under the Amgen deal and $4.2 million under the Daiichi Sankyo agreement. 10, 2015 (GLOBE NEWSWIRE) - Kite Pharma, Inc. Kite Pharma reported a loss of $1.74 per share in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of $1.68 per share as well as the year-ago loss of $0.90 per share.įirst-quarter revenues came in at $9.84 million, below the Zacks Consensus Estimate of $15.30 million but up almost 92% from the year-ago period. Will the recent positive trend continue leading up to the stock's next earnings release, or is it due for a pullback? Before we dive into how investors and analysts have reacted of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. Shares have added about 6.3% in that time frame, outperforming the market. ![]() To read this article on click here.A month has gone by since the last earnings report for Kite Pharma, Inc. ![]() KITE PHARMA INC (KITE): Free Stock Analysis ReportĪLEXION PHARMA (ALXN): Free Stock Analysis Report Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. (ALXN), which carries a Zacks Rank #1 (Strong Buy). Investors interested in the Medical-Biomedical/Generic industry may consider better-ranked stock like Alexion Pharmaceuticals, Inc. KITE currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future, and especially on earnings estimates following the recent slump. The biopharmaceutical company has seen a flat track record when it comes to current year estimate revisions over the past few weeks and the consensus for earnings hasn’t been in a trend either. This breaks the recent trend of the company, as the stock is now trading below the volatile price range of $71.03 to $87.62 since Jan 8, 2015. The move came on pretty good volume too with far more shares changing hands than in a normal session. (KITE) saw a big move last session, as the company’s shares fell by over 9% on the day.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |